Story thread · 2 reports / 2 sources

AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal

endpts.com · 12dShare

More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its

First report: Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. — finance.yahoo.com, 13d